Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Brickabetes

- PMLiVE

Medscape Collaborates for Health Equity at DDW 2023

Recently, DDW 2023 took place in Chicago, IL, and Medscape was on-site with patient advocacy organizations to help educate clinicians on health equity in gastroenterology.Medscape was joined during the conference...

Medscape Education Global

Design-thinking. Iterating for continuous improvement.

How design can lead improvement within Pharma

Mednet Group

Patient Support Program (PSP) Optimization: A Customer Story

Our client was looking to gather detailed feedback on their Patient Support Program (PSP) in order to improve its useability, offerings, and value to patients and caregivers. Working closely with...

Impetus Digital

Hyper-personalisation – The immediate future of pharma is personalised.

What does hyper-personalisation in Pharma look like?

Mednet Group

Virtual Patient Steering Committee: A Customer Story

A French pharmaceutical team contacted Impetus Digital to help them establish a Virtual Steering Committee for patients with HIV/AIDS. They wanted to find a way to directly involve patients in...

Impetus Digital

The Path to Patient Centricity

How do we move towards a more patient-centric way of working?

Mednet Group

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

- PMLiVE

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Research Partnership

- PMLiVE

Oxford PharmaGenesis wins King’s Award following rapid export growth

Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.

Oxford PharmaGenesis

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

Virtual Patient Engagement Program: A Customer Story

Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease...

Impetus Digital

- PMLiVE

Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance affects around 15.5% to 46.5% of the world’s population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links